Proposal would give pioneering drug developers a temporary right to authorize sales of competing drugs that act on the same protein or cellular process
Proposal would give pioneering drug developers a temporary right to authorize sales of competing drugs that act on the same protein or cellular process
On November 14, Patrick Malone, a physician and partner at investment firm KdT Ventures, proposed rewarding teams that first demonstrate in humans that a drug alters a previously untargeted biological pathway, a sequence of linked processes in the body. Under his proposal, competitors would remain free to conduct research.
Different drugs can act on the same protein, known as a drug target. The first team establishes whether a drug can alter that protein's activity in humans and how the body responds. Demonstrating this effect also reduces scientific uncertainty for competitors: they can use that finding to guide their search for their own molecules acting on the same target. The pioneering team bears the cost of the initial test.
The discussion followed an analysis of Convoke's drug development database published on November 12. As of November 11, the most popular 20% of targets accounted for 77% of the drugs in the database that had reached human trials. Drugs were counted regardless of whether they were still in development. The authors expect AI to expand the capacity to design molecules faster than the number of new targets suitable for treatment grows. This would lead even more teams to work on the same biology.
Investor Bruce Booth advised pioneering teams to keep early results confidential for longer to delay the arrival of competitors. Malone proposes giving the first team a temporary exclusive right to commercial use of the shared target:
“Others would still be free to conduct research, but they would need a license to the ‘pathway patent’ to bring a drug to market.”
A company developing a different molecule that acts on the same target would also need a license. The pioneering team could earn revenue from other companies' drugs.
Malone draws a parallel with incentives for orphan drugs, which treat rare diseases. In the US, these drugs receive support under a 1983 law. Once approved, a drug may receive seven years of market exclusivity. Under FDA rules, this restricts approval of the same drug for the same use by other manufacturers. Malone proposes extending protection to a shared target for which different drugs could be developed.
A subsequent drug acting on the same target might last longer or be easier to administer. Its developer would also have to obtain a license from the pioneering team. In the same discussion, Jacob Kimmel, cofounder of the cellular rejuvenation company NewLimit, outlined an approach that would protect a new target within a group of diseases and added a requirement for the rights holder:
“There would be an obligation to grant licenses on reasonable terms.”
The fees and licensing terms would determine both the pioneering team's revenue and the cost of bringing an improved drug to market.
- https://x.com/patricksmalone/status/2121437439705116963
- https://insights.convoke.bio/articles/target-heat-index
- https://t.me/UkhvatNews/4787
- https://www.fda.gov/patients/rare-diseases-fda
- https://www.ecfr.gov/current/title-21/chapter-I/subchapter-D/part-316/subpart-D/section-316.31
- https://x.com/jacobkimmel/status/2121473120720822596